A Bayesian multivariate latent t-regression model for assessing the association between corticosteroid and cranial radiation exposures and cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia: a PETALE study

Table 3 Crude and adjusted population risk differences (PRDs) associated with treatment for individual cardiometabolic risk factors

	PRD^a (95% credible interval)^b
	Crude		Adjusted (including WBC count)		Adjusted (without WBC count)
Obesity
LD/CRT	0.10	(−0.04, 0.23)	0.09	(−0.05, 0.22)	0.11	(−0.03, 0.24)
HD/CRT	0.04	(−0.10, 0.18)	−0.01	(−0.16, 0.15)	0.02	(−0.12, 0.17)
Insulin resistance
LD/CRT	0.04	(−0.06, 0.14)	0.02	(−0.09, 0.13)	0.06	(−0.05, 0.16)
HD/CRT	0.09	(−0.03, 0.20)	0.01	(−0.10, 0.14)	0.07	(−0.05, 0.19)
(Pre-)hypertension
LD/CRT	0.06	(−0.03, 0.15)	0.05	(−0.04, 0.14)	0.04	(−0.05, 0.13)
HD/CRT	0.06	(−0.03, 0.16)	0.06	(−0.05, 0.19)	0.05	(−0.05, 0.17)
Dyslipidemia
LD/CRT	0.14	(0.00, 0.27)	0.15	(0.00, 0.29)	0.12	(−0.02, 0.26)
HD/CRT	0.19	(0.03, 0.34)	0.13	(−0.05, 0.31)	0.08	(−0.08, 0.25)

Point estimates are posterior means based on 10,000 draws. LD low-dose corticosteroids, HD high-dose corticosteroids, CRT cranial radiotherapy, WBC white blood cell. ^a: The baseline treatment level is LD/No CRT. ^b: Endpoints are 2.5 and 97.5 empirical percentiles

ISSN: 1471-2288